Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

[Immune-related adverse events after immune checkpoints inhibitors in 2019: An update].

Comont T, Belliere J, Sibaud V, Alric L, Meyer N, Mazières J, Caron P, Acket B, Michot JM, Beyne-Rauzy O, Lambotte O.

Rev Med Interne. 2020 Jan;41(1):37-45. doi: 10.1016/j.revmed.2019.09.005. Epub 2019 Oct 24. French.

PMID:
31668882
2.

UMOD genetic variations and myeloma cast nephropathy.

Belliere J, Faguer S, Huart A, Ribes D, Chassaing N, Roussel M, Chauveau D.

Clin Kidney J. 2019 Jun 15;12(5):639-640. doi: 10.1093/ckj/sfz071. eCollection 2019 Oct. No abstract available.

3.

Early necrotic skin lesions after a ABO-incompatible kidney transplantation: The threat of Cunninghamella Spp.

Belliere J, Rolland M, Tournier E, Cassaing S, Iriart X, Paul C, Kamar N.

Transpl Infect Dis. 2019 Dec;21(6):e13173. doi: 10.1111/tid.13173. Epub 2019 Oct 21.

PMID:
31529558
4.

Anti-IL-2R blockers comparing with polyclonal antibodies: Higher risk of rejection without negative mid-term outcomes after ABO-incompatible kidney transplantation.

Del Bello A, Divard G, Belliere J, Congy-Jolivet N, Lanfranco L, Ricard R, Delas A, Colombat M, Esposito L, Hebral AL, Cointault O, Lefaucheur C, Loupy A, Kamar N.

Clin Transplant. 2019 Oct;33(10):e13681. doi: 10.1111/ctr.13681. Epub 2019 Sep 8.

PMID:
31369170
5.

Glucocorticoid-free induction regimen in severe ANCA-associated vasculitis using a combination of rituximab and eculizumab.

Ribes D, Belliere J, Piedrafita A, Faguer S.

Rheumatology (Oxford). 2019 Dec 1;58(12):2335-2337. doi: 10.1093/rheumatology/kez190. No abstract available.

PMID:
31102526
6.

No evidence of occult hepatitis C or E virus infections in liver-transplant patients with sustained virological response after therapy with direct acting agents.

Del Bello A, Abravanel F, Alric L, Lavayssiere L, Lhomme S, Bellière J, Izopet J, Kamar N.

Transpl Infect Dis. 2019 Aug;21(4):e13093. doi: 10.1111/tid.13093. Epub 2019 Apr 30.

PMID:
30972874
7.

Percutaneous transluminal angioplasty alone versus stent placement for the treatment of transplant renal artery stenosis.

Macchini M, Mokrane T, Darcourt J, Bellière J, Kamar N, Candelari R, Rousseau H, Meyrignac O.

Diagn Interv Imaging. 2019 Sep;100(9):493-502. doi: 10.1016/j.diii.2019.03.010. Epub 2019 Apr 2.

PMID:
30952527
8.

Incidence of Donor-Specific Anti-HLA Antibodies in Non-HLA-Sensitized Patients Given Tacrolimus Once or Twice Daily During the First 2 Years After Kidney Transplant.

Hage V, Ferrandiz I, Béllière J, Esposito L, Hebral AL, Cointault O, Del Bello A, Kamar N.

Exp Clin Transplant. 2019 Jun;17(3):313-319. doi: 10.6002/ect.2018.0043. Epub 2018 Dec 31.

9.

Complement C5-blocking Agent in Refractory Dermatomyositis.

Faguer S, Belliere J, Ribes D.

J Rheumatol. 2018 Dec;45(12):1710-1711. doi: 10.3899/jrheum.180060. Epub 2018 Sep 15. No abstract available.

PMID:
30219762
10.

Impact of donor BK polyomavirus replication on recipient infections in living donor transplantation.

Grellier J, Hirsch HH, Mengelle C, Esposito L, Hebral AL, Bellière J, Weissbach F, Izopet J, Del Bello A, Kamar N.

Transpl Infect Dis. 2018 Aug;20(4):e12917. doi: 10.1111/tid.12917. Epub 2018 Jun 11.

PMID:
29800505
11.

High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation.

Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Lavayssière L, Esposito L, Hebral AL, Bellière J, Kamar N.

World J Gastroenterol. 2018 Apr 28;24(16):1795-1802. doi: 10.3748/wjg.v24.i16.1795.

12.

Bendamustine plus rituximab for indolent B-cell lymphoma of renal significance.

Ribes D, Hachem HEL, Oberic L, Vergez F, Delas A, Belliere J, Protin C, Kamar N, Ferrandiz I, Tavitian S, Laurent C, Huart A, Chauveau D, Ysebaert L, Faguer S.

Am J Hematol. 2018 Mar;93(3):356-362. doi: 10.1002/ajh.24984. Epub 2017 Dec 6.

13.

Transfusion-acquired hepatitis E infection misdiagnosed as severe critical illness polyneuromyopathy in a heart transplant patient.

Belliere J, Abravanel F, Nogier MB, Martinez S, Cintas P, Lhomme S, Lavayssière L, Cointault O, Faguer S, Izopet J, Kamar N.

Transpl Infect Dis. 2017 Dec;19(6). doi: 10.1111/tid.12784. Epub 2017 Nov 10.

PMID:
28963742
14.

Hepatocyte Nuclear Factor-1β Controls Mitochondrial Respiration in Renal Tubular Cells.

Casemayou A, Fournel A, Bagattin A, Schanstra J, Belliere J, Decramer S, Marsal D, Gillet M, Chassaing N, Huart A, Pontoglio M, Knauf C, Bascands JL, Chauveau D, Faguer S.

J Am Soc Nephrol. 2017 Nov;28(11):3205-3217. doi: 10.1681/ASN.2016050508. Epub 2017 Jul 24.

15.

QuantiFERON test interpretation in patients receiving immunosuppressive agents: an alert.

Belliere J, Blancher A.

Eur Respir J. 2017 Apr 5;49(4). pii: 1602102. doi: 10.1183/13993003.02102-2016. Print 2017 Apr. No abstract available.

16.

Systems biology combining human- and animal-data miRNA and mRNA data identifies new targets in ureteropelvic junction obstruction.

Papadopoulos T, Casemayou A, Neau E, Breuil B, Caubet C, Calise D, Thornhill BA, Bachvarova M, Belliere J, Chevalier RL, Moulos P, Bachvarov D, Buffin-Meyer B, Decramer S, Auriol FC, Bascands JL, Schanstra JP, Klein J.

BMC Syst Biol. 2017 Mar 1;11(1):31. doi: 10.1186/s12918-017-0411-7.

17.

Acute interstitial nephritis related to immune checkpoint inhibitors.

Belliere J, Meyer N, Mazieres J, Ollier S, Boulinguez S, Delas A, Ribes D, Faguer S.

Br J Cancer. 2016 Dec 6;115(12):1457-1461. doi: 10.1038/bjc.2016.358. Epub 2016 Nov 10.

18.

Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and/or viremia.

Belliere J, Kamar N, Mengelle C, Allal A, Sallusto F, Doumerc N, Game X, Congy-Jolivet N, Esposito L, Debiol B, Rostaing L.

Transpl Int. 2016 Mar;29(3):315-22. doi: 10.1111/tri.12718. Epub 2015 Dec 16.

19.

Unmasking Silent Endothelial Activation in the Cardiovascular System Using Molecular Magnetic Resonance Imaging.

Belliere J, Martinez de Lizarrondo S, Choudhury RP, Quenault A, Le Béhot A, Delage C, Chauveau D, Schanstra JP, Bascands JL, Vivien D, Gauberti M.

Theranostics. 2015 Aug 8;5(11):1187-202. doi: 10.7150/thno.11835. eCollection 2015.

20.

Shear Stress-Induced Alteration of Epithelial Organization in Human Renal Tubular Cells.

Maggiorani D, Dissard R, Belloy M, Saulnier-Blache JS, Casemayou A, Ducasse L, Grès S, Bellière J, Caubet C, Bascands JL, Schanstra JP, Buffin-Meyer B.

PLoS One. 2015 Jul 6;10(7):e0131416. doi: 10.1371/journal.pone.0131416. eCollection 2015.

21.

miRNAs in urine: a mirror image of kidney disease?

Papadopoulos T, Belliere J, Bascands JL, Neau E, Klein J, Schanstra JP.

Expert Rev Mol Diagn. 2015 Mar;15(3):361-74. doi: 10.1586/14737159.2015.1009449. Epub 2015 Feb 8. Review.

PMID:
25660955
22.

Calcineurin inhibitor-sparing regimens based on mycophenolic acid after kidney transplantation.

Kamar N, Del Bello A, Belliere J, Rostaing L.

Transpl Int. 2015 Aug;28(8):928-37. doi: 10.1111/tri.12515. Epub 2015 Jan 29. Review.

23.

Tocilizumab added to conventional therapy reverses both the cytokine profile and CD8+Granzyme+ T-cells/NK cells expansion in refractory hemophagocytic lymphohistiocytosis.

Faguer S, Vergez F, Peres M, Ferrandiz I, Casemayou A, Belliere J, Cointault O, Lavayssiere L, Nogier MB, Prevot G, Huart A, Recher C, Rostaing L.

Hematol Oncol. 2016 Mar;34(1):55-7. doi: 10.1002/hon.2174. Epub 2014 Oct 13. No abstract available.

PMID:
25312407
24.

Specific macrophage subtypes influence the progression of rhabdomyolysis-induced kidney injury.

Belliere J, Casemayou A, Ducasse L, Zakaroff-Girard A, Martins F, Iacovoni JS, Guilbeau-Frugier C, Buffin-Meyer B, Pipy B, Chauveau D, Schanstra JP, Bascands JL.

J Am Soc Nephrol. 2015 Jun;26(6):1363-77. doi: 10.1681/ASN.2014040320. Epub 2014 Sep 30.

25.

Beneficial effect of conversion to belatacept in kidney-transplant patients with a low glomerular-filtration rate.

Belliere J, Guilbeau-Frugier C, Del Bello A, Esposito L, Capuani C, Cardeau-Desangles I, Rostaing L, Kamar N.

Case Rep Transplant. 2014;2014:190516. doi: 10.1155/2014/190516. Epub 2014 May 18.

26.

Comparison of the exposure of mycophenolate mofetil and enteric-coated mycophenolate sodium in recipients of kidney-pancreas transplantation.

Belliere J, Esposito L, Gandia P, Duffas JP, Sallusto F, Cardeau-Desangles I, Del Bello A, Rostaing L, Kamar N.

Ann Transplant. 2014 Feb 10;19:76-81. doi: 10.12659/AOT.889691.

27.

Long-term outcome of reusing a kidney allograft retrieved from a living recipient and retransplanted into a second recipient.

Bellière J, Sallusto F, Guilbeau-Frugier C, Rostaing L, Kamar N.

Exp Clin Transplant. 2013 Apr;11(2):203-4. doi: 10.6002/ect.2012.0240. Epub 2013 Feb 22.

28.

Low- versus high-dose rituximab for antibody-mediated rejection after kidney transplantation.

Bellière J, Rostaing L, Guilbeau-Frugier C, Congy N, Kamar N.

Transpl Int. 2013 Feb;26(2):e12-4. doi: 10.1111/tri.12015. Epub 2012 Dec 1. No abstract available.

29.

Prerequisites for ubiquinone analogs to prevent mitochondrial permeability transition-induced cell death.

Belliere J, Devun F, Cottet-Rousselle C, Batandier C, Leverve X, Fontaine E.

J Bioenerg Biomembr. 2012 Feb;44(1):207-12. doi: 10.1007/s10863-012-9406-7. Review. Erratum in: J Bioenerg Biomembr. 2012 Jun;44(3):397.

PMID:
22246424
30.

Ubiquinone analogs: a mitochondrial permeability transition pore-dependent pathway to selective cell death.

Devun F, Walter L, Belliere J, Cottet-Rousselle C, Leverve X, Fontaine E.

PLoS One. 2010 Jul 26;5(7):e11792. doi: 10.1371/journal.pone.0011792.

Supplemental Content

Loading ...
Support Center